Metsera Inc (MTSR)

$52.51 -0.12 (-0.23%)
Market Cap 5.54B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 507,500
Avg Vol 2,211,476
Day's Range N/A - N/A
Shares Out 105.29M
Stochastic %K 13%
Beta N/A
Analysts Strong Sell
Price Target $55.75

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:39 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.71 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $0.29- $0.36 Scale out: $0.45-$0.59 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
StockMeister2
StockMeister2 Oct. 22 at 8:40 PM
Why did Pfizer go with $MTSR instead of $VKTX if VK2735 is so great? https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-metsera-and-its-next-generation-obesity
4 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 5:50 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.86 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 210 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
prototyper
prototyper Oct. 14 at 12:27 AM
$AQST If Barber doesn't announce any partnership by mid Nov to Dec, i m just gonna assume he has shaken hands (BP) under the table. Since they changed PR company, i've noticed Barber likes announcing big news on scheduled events. If no partnership announcement before PDUFA, clearly deal(s) to be announced contingent on approval. IMO, this doesn't need FDA approval to get acquired by big pharma. Pfizer acquired $MTSR few weeks back. I know its completely different beast. Pfizer is buying Metsera while its assets are still in clinical development. If SPRY can get two partnership announcement before PDUFA and we don't, there's something going on behind the curtain. There's no way there's no bite with BPs kicking can down the road.
2 · Reply
FE123
FE123 Oct. 13 at 10:59 AM
$AKRO 5.3 Billion Buyout! $MTSR 7.6 Billion Buyout! $VKTX over $11 Billion!
0 · Reply
biolover
biolover Oct. 11 at 12:30 AM
$MTSR $VKTX going through Metsera doc it is hard not to notice that party 2 ( likely $ABBV ) withdrew its offer ($11 B ) after seeing vesper1 data. Please read below. Metsera management shared data with its board on Aug 17 and signed exclusive agreement with ABBv on that day .. likely provided data and at same time Viking announced its oral data and on sep 2 ABBv CEO decided to withdraw offer. Just surprised of his reasoning according to Metsera but who cares BTW no one does these moves except Abbv
1 · Reply
biolover
biolover Oct. 10 at 11:14 PM
$MTSR $VKTX talking about Metsera. I look forward to hearing Pfizer answers to analysts about tolerability from vesper 1 and efficacy from vesper 3. Both undeclared by Metsera.
0 · Reply
GPTInsights
GPTInsights Oct. 10 at 10:20 PM
$VKTX Well right around $31 is a 3.5 billion market cap. That would be less than half of the deal $MTSR got from Pfizer with an inferior pipeline that is a couple years behind Viking and with less cash on hand than Viking.
0 · Reply
FE123
FE123 Oct. 10 at 9:45 PM
$VKTX Just Mentioned $MTSR buyout! Accelerate M&A going Forward!
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 3:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.84 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 218 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
Latest News on MTSR
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

Oct 23, 2025, 12:15 PM EDT - 2 days ago

Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

PFE

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Sep 30, 2025, 3:39 PM EDT - 24 days ago

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

PFE

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Sep 30, 2025, 11:02 AM EDT - 25 days ago

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

PFE

Metsera's obesity drug shows promising weight loss in mid-stage trials

Sep 29, 2025, 4:11 PM EDT - 25 days ago

Metsera's obesity drug shows promising weight loss in mid-stage trials

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

Sep 29, 2025, 4:01 PM EDT - 25 days ago

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

Sep 23, 2025, 6:00 PM EDT - 4 weeks ago

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

PFE

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Sep 22, 2025, 2:50 PM EDT - 4 weeks ago

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

PFE

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Sep 22, 2025, 2:01 PM EDT - 4 weeks ago

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

PFE

Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades

Sep 22, 2025, 10:01 AM EDT - 4 weeks ago

Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades

AAPL PFE MS

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

Sep 22, 2025, 9:16 AM EDT - 4 weeks ago

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

PFE

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Sep 22, 2025, 9:09 AM EDT - 4 weeks ago

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

PFE

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Sep 22, 2025, 8:59 AM EDT - 4 weeks ago

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

PFE

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

Sep 22, 2025, 8:14 AM EDT - 4 weeks ago

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

PFE

Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight

Sep 22, 2025, 8:05 AM EDT - 4 weeks ago

Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight

INTC PFE

This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

Sep 22, 2025, 7:42 AM EDT - 4 weeks ago

This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

PFE

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

Sep 22, 2025, 7:02 AM EDT - 4 weeks ago

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

PFE

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

Sep 22, 2025, 6:54 AM EDT - 4 weeks ago

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

PFE

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

Sep 22, 2025, 6:45 AM EDT - 4 weeks ago

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

PFE

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

Sep 22, 2025, 1:55 AM EDT - 4 weeks ago

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

PFE

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

Sep 22, 2025, 12:04 AM EDT - 4 weeks ago

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

PFE

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

Sep 11, 2025, 7:00 AM EDT - 6 weeks ago

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

Metsera to Present at Upcoming September Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 2 months ago

Metsera to Present at Upcoming September Investor Conferences

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Jul 28, 2025, 4:01 PM EDT - 3 months ago

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Jun 9, 2025, 2:07 PM EDT - 4 months ago

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Jun 9, 2025, 12:04 PM EDT - 4 months ago

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Jun 5, 2025, 7:30 AM EDT - 5 months ago

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

May 12, 2025, 7:00 AM EDT - 5 months ago

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Bank of America 2025 Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 6 months ago

Metsera to Present at Bank of America 2025 Global Healthcare Conference

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 7:00 AM EST - 8 months ago

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Feb 26, 2025, 3:55 AM EST - 8 months ago

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Why this newly public biotech could become a force in obesity treatments

Feb 25, 2025, 1:42 PM EST - 8 months ago

Why this newly public biotech could become a force in obesity treatments

This weight-loss drug stock could deliver a 90% return in 2025

Feb 25, 2025, 8:47 AM EST - 8 months ago

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

Feb 5, 2025, 4:01 PM EST - 9 months ago

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 9 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE ODTX ODYS SAIL

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Jan 31, 2025, 12:42 PM EST - 9 months ago

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Weight-loss drug developer Metsera raises $275 million in US IPO

Jan 30, 2025, 7:05 PM EST - 9 months ago

Weight-loss drug developer Metsera raises $275 million in US IPO

Metsera Announces Pricing of Initial Public Offering

Jan 30, 2025, 6:53 PM EST - 9 months ago

Metsera Announces Pricing of Initial Public Offering

Metsera Readies $275 Million IPO For Obesity Treatments

Jan 28, 2025, 4:48 PM EST - 9 months ago

Metsera Readies $275 Million IPO For Obesity Treatments

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:39 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.71 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $0.29- $0.36 Scale out: $0.45-$0.59 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
StockMeister2
StockMeister2 Oct. 22 at 8:40 PM
Why did Pfizer go with $MTSR instead of $VKTX if VK2735 is so great? https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-metsera-and-its-next-generation-obesity
4 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 5:50 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.86 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 210 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
prototyper
prototyper Oct. 14 at 12:27 AM
$AQST If Barber doesn't announce any partnership by mid Nov to Dec, i m just gonna assume he has shaken hands (BP) under the table. Since they changed PR company, i've noticed Barber likes announcing big news on scheduled events. If no partnership announcement before PDUFA, clearly deal(s) to be announced contingent on approval. IMO, this doesn't need FDA approval to get acquired by big pharma. Pfizer acquired $MTSR few weeks back. I know its completely different beast. Pfizer is buying Metsera while its assets are still in clinical development. If SPRY can get two partnership announcement before PDUFA and we don't, there's something going on behind the curtain. There's no way there's no bite with BPs kicking can down the road.
2 · Reply
FE123
FE123 Oct. 13 at 10:59 AM
$AKRO 5.3 Billion Buyout! $MTSR 7.6 Billion Buyout! $VKTX over $11 Billion!
0 · Reply
biolover
biolover Oct. 11 at 12:30 AM
$MTSR $VKTX going through Metsera doc it is hard not to notice that party 2 ( likely $ABBV ) withdrew its offer ($11 B ) after seeing vesper1 data. Please read below. Metsera management shared data with its board on Aug 17 and signed exclusive agreement with ABBv on that day .. likely provided data and at same time Viking announced its oral data and on sep 2 ABBv CEO decided to withdraw offer. Just surprised of his reasoning according to Metsera but who cares BTW no one does these moves except Abbv
1 · Reply
biolover
biolover Oct. 10 at 11:14 PM
$MTSR $VKTX talking about Metsera. I look forward to hearing Pfizer answers to analysts about tolerability from vesper 1 and efficacy from vesper 3. Both undeclared by Metsera.
0 · Reply
GPTInsights
GPTInsights Oct. 10 at 10:20 PM
$VKTX Well right around $31 is a 3.5 billion market cap. That would be less than half of the deal $MTSR got from Pfizer with an inferior pipeline that is a couple years behind Viking and with less cash on hand than Viking.
0 · Reply
FE123
FE123 Oct. 10 at 9:45 PM
$VKTX Just Mentioned $MTSR buyout! Accelerate M&A going Forward!
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 3:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MTSR Current Share Price: $52.84 Contracts: $MTSR May 15, 2026 $55 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 218 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
JusKallmeGravy
JusKallmeGravy Oct. 9 at 2:48 PM
$MTSR $PFE $VKTX This is spot on.
0 · Reply
GPTInsights
GPTInsights Oct. 9 at 2:45 PM
$VKTX Currently by market cap $PFE is listed at #9 on the list of biggest biomed companies. Their weight has fallen substantially in the last couple years. My best guess is they settled on $MTSR because they could not make a competitive offer for Viking. Even looking at Metsera's filing and seeing how many companies they were in talks with it looks like Pfizer was lucky to get what they did. It is a fair to assume many of those same and potentially (probably) more companies are pursuing Viking. The efficacy to outshine Mounjaro/Zepbound commands a hefty premium.
0 · Reply
biolover
biolover Oct. 9 at 10:29 AM
$AKRO $LLY $MTSR $NVO $VKTX But they are selling at modest premium like this $NVO $AKRO deal. I still believe managements that sells at low premium having doubts about repeating phase 2 outcome in phase 3. If AkRO management believed could do as good in phase 3. This should have been > $10 B deal. All are worried about GLP1 / GIP / Glucagon competition due to pleiotropic benefits of this class that drugs such as FGF21 don’t provide .. $VKTX drugs will be king one day.
2 · Reply
biolover
biolover Oct. 9 at 10:20 AM
$VKTX Was $NVO acquiring $MTSR and $AKRO at same time ? May be… may be not ? Party 1 at Metsera deal still a mystery .? Novo sees an opportunity in MASH. $LLY is running phase 3 for both tirzepatide and retatrutide vs placebo in MASH. Both drugs clearly more effective than semaglutide from phase 2. But this phase 3 doesn’t include a biopsy and will be difficult to compare to Sema phase 3 although clinical outcome may determine long term usage and thus novo wanted to consolidate outcome through Akero . Still 2 most underestimated MASH actors long term retatrutide ( presuming cardiac safety ) and $VKTX VK2735
0 · Reply
FE123
FE123 Oct. 9 at 2:14 AM
$VKTX Good day to drop the good news tomorrow! Same price as $MTSR when they announced Buyout!
0 · Reply
heyupikachu1821
heyupikachu1821 Oct. 8 at 10:15 PM
$VKTX bought into this stock with a very small amount, since I thought it might pullback further following $MTSR acquisition. It’s been outperforming my expectations though and I think I need to up my shares
1 · Reply
FE123
FE123 Oct. 8 at 5:34 PM
$VKTX This was price of $MTSR when buyout was announced!!
0 · Reply
MusicBox
MusicBox Oct. 8 at 5:19 PM
$PFE $MTSR Down 50%, Should You Buy the Dip on Pfizer? Pfizer Pfizer is a leading global pharmaceutical firm with a strong history of drug discovery, development, and commercialization. The recent stock price movement may interest turnaround investors.
0 · Reply
raticals
raticals Oct. 8 at 3:13 PM
$VKTX Viking is better than Metsera $MTSR in every single way. Cash on hand. Stage of trials progression wise. WAY less pukers. Way more transparent on data. Both injectable and pill work better efficacy wise. Have a developed MASH asset. Have Amylin in hopper. Doing maintenance studies. And 7 wanted Metsera and 3 did badly for $7 billion minimum. And here Viking sits at $3.5 valuation. Peel the onion back and I think Viking has minimum 2-3 $100 offers at present.
3 · Reply
raticals
raticals Oct. 8 at 2:50 PM
$VKTX this was $42 before oral data. If they pulled a $MTSR and announced AE at 12 weeks instead of at start, we would be over $60 now
0 · Reply
Power2k
Power2k Oct. 7 at 1:23 PM
$VKTX The $PFE / $MTSR deal confirms we are worth at least 10B. We also have VK2809 which is a better version of TRb agonist than $MDGL 's. C'mon, let's push it up to 15B. $NVO
1 · Reply
Power2k
Power2k Oct. 7 at 12:39 PM
$VKTX Did you all notice that Party 2 proposed an exclusive bid at $95/share (~10B) on $MTSR at the moment when MTSR was traded at $32 around 8/17/25. We're exactly at $32 now, just saying... BTW, Party 2 could very likely be $NVO as their new CEO announced a global layoff of 9,000 employees on Sept 10th - that might have triggered the termination of the Exclusivity deal they proposed on Aug 17th. $MRK $LLY
1 · Reply